ATXS: Astria Therapeutics Inc Price to Sales
Can Astria Therapeutics (ATXS) commercialize antibodies to combat hereditary angioedema? The multi-disciplinary nature of clinical trials for rare pathologies minimizes risks. The application of AI and robotics accelerates drug synthesis, which is supported by the median P/S. The value of 997.10 shows the latest reading of this indicator, which strips emotional noise from market data by capturing the price-to-sales ratio.
Metric breakdowns and analytics for Astria Pharma (ATXS)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Astria Therapeutics|ATXS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Astria Corp|ATXS - Company Aggregate Debts|Debts to Net Assets Astria Pharma|ATXS - Company Long-Term Debts|Company Short-Term Debts Astria Therapeutics|Intermediate Coverage Ratio astriatx.com
- company profitability and valuation multiples indicators:
ATXS - Net Income|Future Net Profit Astria Therapeutics|ATXS - P/E Multiple|Future Price to Earnings Multiple Astria Therapeutics Inc|ATXS - PEG Multiple|Company Value to EBITDA Astria Pharma|ATXS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Astria Therapeutics|ATXS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth astriatx.com|ATXS - Earnings per share growth in current year|Net earnings per share change forecast for next year Astria Therapeutics
- total revenue and sales volume data:
General company analysis:ATXS, astriatx.com
When screening issuer reliability, the P/S ratio allows for an assessment of a business's market value relative to its revenue, determining the premium paid per unit of sales. For Astria Therapeutics (ATXS), which is burdened by R&D costs without operating leverage, this metric is critical, as the price/sales ratio trend reflects only speculative market expectations of future revenues prior to drug commercialization.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|Market Cap to Revenue GRFS|ADPT (Adaptive Biotech) - Market Cap to Sales Volume|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PGEN|PHAR (pharming.com) - Market Cap to Sales Volume|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio (IMNM) - Price to Sales|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|Pieris Pharma (PVLA) - P/S Multiple|Price-to-Revenue Ratio Savara Corp|Rigel Corp - Price-to-Sales Ratio|P/S Multiple ANAB|ENGN - Price to Sales|RAPT Therapeutics - Market Cap to Revenue|P/S Multiple Aerovate Therapeutics, Inc. JBIO|ACRS: Market Cap to Revenue|Kyverna Therapeutics, Inc - Market Cap to Sales Volume|TLSA: P/S Multiple|CABA - Price-to-Revenue Coefficient|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Market Cap to Revenue Theratechnologies, Inc. (THTX)|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|ZURA: Market Cap to Revenue|aTyr Pharma Inc - Market Cap to Sales Volume|ADAG (adagene.com) - Market Cap to Revenue|Market Cap to Revenue Ratio IMA|Price-to-Revenue Ratio Shattuck Labs Inc|Equillium Bio (EQ) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX: Price-to-Sales Ratio|P/S Multiple ATRA (Atara Bio)|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com (SCNI) - Price-to-Revenue Coefficient|Market Cap to Revenue CALI (CalciMedica, Inc.)|Market Cap to Sales Volume AFMD|Price-to-Revenue Ratio Allakos ALLK|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Market Cap to Revenue THRD
